Ulka N. Vaishampayan, MD, on challenges facing patients and providers
Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, describes the biggest challenges facing patients and providers in the diagnosis and treatment strategies for metastatic renal cell carcinoma patients.
Ana Aparicio, MD, explains data and conclusions from her presentation at ASCO GU 2017
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, briefly relays the data and conclusions from her presentation, “Advances in the Understanding and Treatment of AR-Indifferent Disease” at ASCO GU.
Nicholas J. Vogelzang, MD, FASCO, FACP, on treating metastatic prostate cancer with multiple drugs
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, shares his thoughts on how to integrate multiple drugs into treatment for metastatic prostate cancer.
Robert B. Den, MD, give his thoughts on the most intriguing research presented at ASCO GU
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, relays the most intriguing research presentations at ASCO GU 2017.
Jeffrey M. Holzbeierlein, MD, highlights the most promising data coming out of ASCO GU 2017
Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, on the most promising data showcased at ASCO GU.
Neal D. Shore, MD, FACS, provides insight into data on resistance and advanced prostate cancer
Dr. Shore, MD, Director, Carolina Urologic Research Center, gives his perspective on how the treatment of advanced prostate cancer has changed with recent emerging data on resistance.
Ana Aparicio, MD, on how to sequence commonly used agents in metastatic prostate cancer
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, gives her perspective on the proper way to sequence commonly used agents in metastatic prostate cancer.
Nicholas J. Vogelzang, MD, FASCO, FACP, discusses resistance and advanced prostate cancer
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains how the treatment of advanced prostate cancer has changed with recent emerging data on resistance.
Robert B. Den, MD, discusses the recent changes in radiation treatment for invasive bladder cancer
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, on how radiation has changed invasive bladder cancer treatment.
David J. McConkey, PhD, on which drugs have the highest potential to impact bladder cancer treatment
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, gives his views on which specific drugs have the greatest potential to make significant impact in bladder cancer treatment.
Mohamad E. Allaf, MD, on immunotherapies and renal cell carcinoma treatment algorithms
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, gives information on immunotherapies being integrated into renal cell carcinoma treatment algorithms.
Jeffrey M. Holzbeierlein, MD, offers his opinion on interesting presentations from ASCO GU 2017
Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, discusses intriguing data and presentations from ASCO GU.
Neal D. Shore, MD, FACS, explains the impact of CHAARTED and STAMPEDE
Dr. Shore, MD, Director, Carolina Urologic Research Center, details how CHAARTED and STAMPEDE influenced his treatment of metastatic hormone sensitive prostate cancer patients.
Matthew I. Milowsky, MD, outlines treating bladder cancer with checkpoint inhibitors
Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, explains what physicians need to know about the progress being made treating bladder cancer with checkpoint inhibitors.
Eric Jonasch, MD, on integrating immunotherapies into renal cell carcinoma treatment algorithms
Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, on how immunotherapies are being integrated into renal cell carcinoma treatment algorithms.
Ana Aparicio, MD, on immunotherapy as a future treatment guideline for metastatic prostate cancer
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, talks about if immunotherapy will be added as treatment guidelines for metastatic prostate cancer patients in the near future.
Nicholas J. Vogelzang, MD, FASCO, FACP, on immunotherapy and metastatic prostate cancer
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, offers feedback on if immunotherapy will be added to metastatic prostate cancer treatment guidelines in the near future.
Freddie C. Hamdy, MD, offers his opinion on exciting research from ASCO GU 2017
Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, gives his thoughts on the most exciting items learned through this meeting and what awareness should be brought to other clinicians.
David J. McConkey, PhD, on treating bladder cancer with checkpoint inhibitors
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses what physicians need to know regarding the progress accomplishments achieved in treating bladder cancer with checkpoint inhibitors.
Mohamad E. Allaf, MD, provides insight into treating metastatic non-clear cell renal cell carcinoma
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, describes the approach physicians should consider when treating metastatic non-clear cell renal cell carcinoma, given the limited clinical evidence.
Ulka N. Vaishampayan, MD, on immunotherapies and renal cell carcinoma treatment algorithms
Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, provides insight into how immunotherapies are being integrated into renal cell carcinoma treatment algorithms.
Jeffrey M. Holzbeierlein, MD, gives his perspective on treatment trends in urology for 2017
Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, discusses treatment trends in urology for 2017 and beyond.
Neal D. Shore, MD, FACS, on where chemotherapy fits into prostate cancer treatment
Dr. Shore, MD, Director, Carolina Urologic Research Center, describes where chemotherapy fits into treatment for prostate cancer.
Alexandra Drakaki, MD, PhD, shares highlights from sessions in bladder cancer at ASCO GU 2017
Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, reveals highlights from sessions in bladder cancer at ASCO GU.
Matthew I. Milowsky, MD, explains how genomics are changing the way we treat bladder cancer subtypes
Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, describes how genomics are changing the way we treat bladder cancer subtypes.
Eric Jonasch, MD, on targeted therapies used to treat non-clear cell renal cell carcinoma
Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, gives information on using targeted therapies to treat non-clear renal cell carcinoma.
Aly-Khan Lalani, MD, shares the results of his ASCO GU 2017 poster session
Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, discusses the results of his ASCO GU poster session.
Ana Aparicio, MD, on commercial AR-V7 tests and metastatic castrate-resistant prostate cancer
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, provides her opinion on how a commercial AR-V7 test will impact initial and subsequent choice of therapies for metastatic castrate-resistant prostate cancer.
Nicholas J. Vogelzang, MD, FASCO, FACP, explains the influence of CHAARTED and STAMPEDE
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, discusses how CHAARTED and STAMPEDE influences his treatment of metastatic hormone-sensitive prostate cancer patients.
Robert B. Den, MD, on which patients with low-risk prostate cancer should receive radiation
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, weighs in on which patients with low-risk prostate cancer should receive radiation.
Freddie C. Hamdy, MD, on putting into practice what we’ve learned from the ProtecT study
Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, gives his view on how side effects of surgery, radiation, and active surveillance for the ProtectT study, warrant choosing one over the other for metastatic prostate cancer patients.
David J. McConkey, PhD, provides information on treating bladder cancer with checkpoint inhibitors
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses what physicians need to know regarding the progress accomplishments achieved in treating bladder cancer with checkpoint inhibitors.
Mohamad E. Allaf, MD, shares the most intriguing research presented at ASCO GU 2017
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, provides his opinion on what research presented at ASCO GU was most interesting.
Eric Jonasch, MD, on approaches to consider with metastatic non-clear renal cell carcinoma
Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, on the approaches (based on limited clinical evidence) physicians need to be considering when treating metastatic non-clear cell renal cell carcinoma.
Aly-Khan Lalani, MD, offers feedback on using immunotherapies to treat renal cell carcinoma patients
Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, on the optimistic view of using immunotherapies to treat renal cell carcinoma patients.
Ana Aparicio, MD, discusses where chemotherapy fits in regard to prostate cancer treatment
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center, on the fit of chemotherapy for prostate cancer treatment.
Nicholas J. Vogelzang, MD, FASCO, FACP, on BRCA1 and BRCA2 genetic testing as guidelines
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, weighs in on if genetic testing for BRCA1 and BRCA2 genetic should be added to prostate cancer guidelines.
Robert B. Den, MD, on the QOL differences between clinically localized prostate cancer patients
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, explains how QOL for a clinically localized prostate cancer patient receiving radiation differs from the QOL of those patients receiving surgery or active surveillance.
Freddie C. Hamdy, MD, elaborates on factors from the ProtecT study
Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, discusses how the surgery, radiation, and active surveillance arms of the ProtecT study were differentiated in terms of overall survival for metastasis free patients.
David J. McConkey, PhD, on non-invasive imaging and monitoring metastatic bladder cancer
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, opines on whether non-invasive imaging is ready for the masses, and which methods oncologists should be using to stage and monitor metastatic bladder cancer.
Mohamad E. Allaf, MD, on helping non-metastatic renal cell carcinoma patients with adjuvant therapy
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, discusses the hope that we may be able to help non-metastatic renal cell carcinoma patients with adjuvant therapy.
Ulka N. Vaishampayan, MD, on metastatic renal cell carcinoma patients and chemotherapy
Dr. Vaishampayan, MD, Department of Oncology, Karmanos Cancer Institute, explains the types of metastatic renal cell carcinoma patients that should be treated with chemotherapy.
Jeffrey M. Holzbeierlein, MD, on the impact of his data presented at ASCO GU 2017
Dr. Holzbeierlein, MD, Associate Professor of Urology, University of Kansas Hospital, explains the impact his data, as presented in “General Session 6: Orphan Cancers with Opportunities for Improved Treatment (ARS),” could have on clinicians currently in the field.
Neal D. Shore, MD, FACS, on metastatic castration-resistant prostate cancer patients
Dr. Shore, MD, Director, Carolina Urologic Research Center, on which metastatic castration-resistant prostate cancer patients should receive chemotherapy.
Alexandra Drakaki, MD, PhD, on what we need to know about checkpoint inhibitors and bladder cancer
Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, discusses what physicians need to know about the progress being made with treating bladder cancer with checkpoint inhibitors.
Matthew I. Milowsky, MD, on the role of genomics in understanding heterogeneity in bladder cancer
Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, explains how genomics are helping physicians better understand heterogeneity in bladder cancer.
Eric Jonasch, MD, on treating non-metastatic renal cell carcinoma patients with adjuvant therapy
Dr. Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, provides opinion on treating non-metastatic renal cell carcinoma patients with adjuvant therapy.
Aly-Khan Lalani, MD, examines the integration of immunotherapies for renal cell carcinoma treatment
Dr. Lalani, MD, Genitourinary Oncology Fellow, Dana Farber Cancer Institute, on how immunotherapies are being integrated into renal cell carcinoma treatment algorithms.
Ana Aparicio, MD, discusses the impact of CHAARTED and STAMPEDE on her treatment decisions
Dr. Aparicio, MD, Associate Professor, The University of Texas MD Anderson Cancer Center on how CHAARTED and STAMPEDE impacted her treatment decisions for metastatic hormone sensitive prostate cancer patients.
Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients
Dr. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, explains which metastatic castration-resistant prostate cancer patients, are the right ones to be treated with chemotherapy.
Robert B. Den, MD, on the recent adoption of radiation treatment for advanced prostate cancer
Dr. Den, MD, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, provides his feedback on how radiation has been recently adopted for advanced prostate cancer treatment.
Freddie C. Hamdy, MD, informs us on the ProtecT study top line results
Dr. Hamdy, MD, Head of the Nuffield Department of Surgery, University of Oxford, relays the top line results for the ProtecT study.
David J. McConkey, PhD, on the responses to immunotherapy for varied bladder cancer subtypes
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, explains his views on why some bladder cancer subtypes respond better to immunotherapy than others.
David J. McConkey, PhD, on the influence of genomics for the treatment of bladder cancer subtypes
Dr. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, discusses the impact genomics have in the way bladder cancer subtypes are being treated.
Mohamad E. Allaf, MD, on non-metastatic renal cell cancer patients and adjuvant therapy
Dr. Allaf, MD, Vice Chairman, Department of Urology, Associate Professor of Urology, Johns Hopkins University School of Medicine, weighs in on which non-metastatic renal cell cancer patients should receive adjuvant therapy.
Ulka N. Vaishampayan, MD, provides her opinion on the most interesting research at ASCO GU 2017
Dr. Vaishampayan, Department of Oncology, Karmanos Cancer Institute, discusses the most intriguing research presented at ASCO GU.
Nicholas J. Vogelzang, MD, FASCO, FACP, discusses the influence of an AR-V7 commercial test
Nicholas J. Vogelzang, MD, FASCO, FACP, Medical Oncologist, Comprehensive Cancer Centers of Nevada, on the impact a commercial AR-V7 test will have on the initial and subsequent choice of therapies for metastatic castrate-resistant prostate cancer.
Neal D. Shore, MD, FACS, on the impact of an AR-V7 commercial test
Dr. Shore, MD, Director, Carolina Urologic Research Center, explains how an AR-V7 commercial test will affect initial and subsequent choice of therapies for metastatic castrate-resistant prostate cancer.
Jeffrey M. Holzbeierlein, MD, summarizes data and conclusions from his presentation at ASCO GU 2017
Dr. Holzbeierlein, Associate Professor of Urology, University of Kansas Hospital, describes the data and conclusions he presented in “General Session 6: Orphan Cancers with Opportunities for Improved Treatment (ARS)” at ASCO GU.
Neal D. Shore, MD, FACS, on BRCA1 and BRCA2 genetic testing as guidelines for prostate cancer
Dr. Shore, MD, Director, Carolina Urologic Research Center, offers his opinion on whether or not BRCA1 and BRCA2 genetic testing should be added to guidelines for prostate cancer.
Alexandra Drakaki, MD, PhD, describes her work with microRNA and the potential clinical implications
Dr. Drakaki, MD, PhD, Assistant Professor, Division of Hematology Oncology, David Geffen School of Medicine at UCLA, offers thoughts on her work with microRNA and the potential clinical implications.
Matthew I. Milowsky, MD, shares highlights from his lecture on urothelial carcinoma
Dr. Milowsky, Associate Professor, University of North Carolina at Chapel Hill School of Medicine, offers key takeaways and highlights from his lecture, “Urothelial Carcinoma: Year in Review” at ASCO GU.
Eric Jonasch, MD, on which non-metastatic renal cell cancer patients should receive adjuvant therapy
Dr. Jonasch, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, provides insight into which specific non-metastatic renal cell cancer patients should receive adjuvant therapy.
Aly-Khan Lalani, MD, provides feedback on which ASCO GU research presentations were most intriguing
Dr. Lalani, Medical Oncology, Dana Farber Cancer Institute, on the most intriguing research presentations here at ASCO GU.
Ana Aparicio, MD, on metastatic castration-resistant prostate cancer patients and chemotherapy
Dr. Aparicio, Associate Professor, The University of Texas MD Anderson Cancer Center, provides insight into who the right metastatic castration-resistant prostate cancer patients are that should be treated with chemotherapy.
Robert B. Den, MD, considers topics in the “Best of Journals: Prostate Cancer” panel discussion
Dr. Den, Associate Professor, Co-Director, Multidisciplinary Genitourinary Oncology Center, Sidney Kimmel Medical College at Thomas Jefferson University, on which topics will be addressed in the in the “Best of Journals: Prostate Cancer” panel discussion.
Freddie C. Hamdy, MD, on how the design of the ProtecT study works
Dr. Hamdy, Head of the Nuffield Department of Surgery, University of Oxford, explains how the ProtecT study was designed.
David J. McConkey, PhD, discusses how genomics helps us understand heterogeneity in bladder cancer
David J. McConkey, PhD, Director of the Johns Hopkins Greenberg Bladder Cancer Institute, relays the importance of genomics to help us understand heterogeneity in bladder cancer
Nicholas J. Vogelzang, MD, on where chemotherapy fits into treatment for prostate cancer
Dr. Vogelzang, Medical Oncologist, Comprehensive Cancer Centers of Nevada, on where chemotherapy fits into treatment for prostate cancer
